Year 0 (enrolment) | | | | | | | |
6MWD m | 979 | 1.16 (0.05–2.27) | 0.04 | 1.30 (0.01–2.60) | 0.049 | 0.66 (−1.60–2.90) | ns |
mMRC | 961 | −0.004 (−0.01–0.01) | ns | 0.0006 (−0.01–0.01) | ns | −0.02 (−0.04– −0.002) | 0.03 |
SGRQ | 965 | −0.20 (−0.37– −0.02) | 0.03 | −0.10 (−0.30–0.10) | ns | −0.52 (−0.88– −0.15) | 0.006 |
BODE index | 939 | −0.02 (−0.04– −0.001) | 0.04 | −0.02 (−0.05– −0.0001) | 0.049 | −0.01 (−0.05–0.03) | ns |
GOLD stage | 996 | −0.01 (−0.02– −0.006) | <0.001 | −0.02 (−0.02– −0.01) | <0.001 | −0.003 (−0.02–0.009) | ns |
PD-FEV1 mL | 996 | 6.9 (2.5–11.3) | 0.002 | 9.2 (4.1–14.3) | <0.001 | −1.3 (−10.2–7.6) | ns |
PD-FEV1 % predicted | 996 | 0.25 (0.10–0.39) | 0.001 | 0.31 (0.15–0.48) | <0.001 | 0.02 (−0.27–0.30) | ns |
LAA% | 887 | −0.12 (−0.22–−0.01) | 0.03 | −0.15 (−0.28–−0.02) | 0.02 | 0.02 (−0.17–0.21) | ns |
CVD history | 996 | 1.04§ (1.02–1.07) | <0.001 | 1.06§ (1.03–1.08) | <0.001 | 1.01§ (0.96–1.05) | ns |
Agaston score total | 362 | 7.3 (−5.3–19.9) | ns | 2.9 (−11.3–17.2) | ns | 22.5 (−3.7–48.6) | ns |
Year 1 (MFAP4 measurement) | | | | | | | |
IL-6 pg·mL−1 | 860 | 0.01 (−0.11–013) | ns | −0.02 (−0.18–0.14) | ns | 0.10 (−0.04–0.24) | ns |
Fibrinogen mg·dL−1 | 969 | −1.3 (−2.3– −0.3) | 0.01 | −1.4 (−2.5– −0.3) | 0.01 | −0.7 (−2.8–1.5) | ns |
PD-FEV1 mL | 996 | 5.1 (0.4–9.7) | 0.03 | 7.2 (1.8–12.5) | 0.008 | −2.5 (−12.0–7.1) | ns |
PD-FEV1 % predicted | 996 | 0.19 (0.04–0.34) | 0.02 | 0.24 (0.07–0.41) | 0.006 | −0.01 (−0.31–0.30) | ns |
PD-FVC mL | 996 | −0.4 (−7.7–6.9) | ns | 0.2 (−8.0–8.6) | ns | −3.8 (−18.9–11.4) | ns |
PD-FEV1/FVC % | 996 | 0.2 (0.1–0.3) | 0.001 | 0.2 (0.1–0.4) | <0.001 | −0.02 (−0.2–0.2) | ns |
ΔFEV1 mL year 1−year 0 | 996 | −1.9 (−4.1–0.03) | ns | −2.0 (−4.2–0.3) | ns | −1.7 (−6.8–3.4) | ns |
Exacerbations | 996 | −0.012 (−0.026–0.002) | ns | −0.017 (−0.034– −0.0005) | 0.043 | 0.003 (−0.024–0.030) | ns |
PD15 g·L−1 | | 0.4 (0.2–0.6) | 0.001 | 0.5 (0.2–0.8) | <0.001 | 0.08 (−0.04–0.6) | ns |
LAA% | 948 | −0.15 (−0.25– −0.04) | 0.006 | −0.19 (−0.32– −0.06) | 0.004 | 0.01 (−0.18–0.20) | ns |
ΔLAA% year 1−year 0 | 887 | −0.012 (−0.048–0.024) | ns | −0.021 (−0.065–0.024) | ns | 0.017 (−0.047–0.081) | ns |
Year 3 (follow-up) | | | | | | | |
PD-FEV1 mL | 925 | 5.4 (0.4–10.3) | 0.03 | 7.5 (1.7–13.4) | 0.01 | −1.3 (−10.8–8.3) | ns |
PD-FEV1 % predicted | 925 | 0.21 (0.05–0.37) | 0.01 | 0.28 (0.09–0.47) | 0.004 | −0.005 (−0.31–0.30) | ns |
ΔFEV1 mL year 3−year 1 | 925 | 1.0 (−1.2–3.3) | ns | 1.6 (−0.9–4.1) | ns | −0.5 (−5.3–4.3) | ns |
Exacerbations | 995 | −0.014 (−0.028–0.00003) | ns | −0.015 (−0.03–0.002) | ns | −0.013 (−0.040–0.015) | ns |
LAA% | 876 | −0.17 (−0.30– −0.04) | 0.009 | −0.19 (−0.3– −0.03) | 0.02 | −0.09 (−0.31–0.12) | ns |
ΔLAA% year 3−year 1 | 876 | 6.1×10–6 (−0.05–0.05) | ns | 0.03 (−0.03–0.08) | ns | −0.06 (−0.15–0.02) | ns |
Death | 996 | 1.04§ (1.01–1.08) | 0.02 | 1.04§ (1.01–1.08) | 0.02 | 0.95§ (0.74–1.22) | ns |